Lung Cancer Research Foundation and AstraZeneca Launch $750K SCLC Research Initiative
Event summary
- Lung Cancer Research Foundation (LCRF) and AstraZeneca launch two grants totaling $750,000 to advance small cell lung cancer (SCLC) research.
- Grants include $500,000 for treatment strategies and $250,000 for patient advocacy initiatives.
- SCLC accounts for 13-15% of lung cancer cases with a 5-year survival rate of less than 7%.
- AstraZeneca's Nabil Chebab and LCRF's Dr. Antoinette Wozniak highlight collaboration to address unmet needs in SCLC.
The big picture
The collaboration between LCRF and AstraZeneca addresses a critical gap in SCLC research, an area that has seen limited progress compared to non-small cell lung cancer (NSCLC). With SCLC's aggressive nature and low survival rates, this initiative aims to accelerate discoveries and improve patient outcomes through targeted research and advocacy efforts. The $750,000 investment underscores the urgent need for innovative approaches in treating this challenging disease.
What we're watching
- Research Progress
- The pace at which novel treatment strategies for SCLC will emerge from this collaboration.
- Patient Advocacy Impact
- How patient advocacy initiatives will influence research priorities and outcomes in SCLC.
- Industry Collaboration
- Whether this partnership will spur additional investments in SCLC research from other biopharma companies.